Denali Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-512.00
-422.00
-145.00
-325.00
-291.00
71.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
0.00
16.00
-289.00
-24.00
-20.00
288.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-412.00
-347.00
-357.00
-244.00
-211.00
416.00
Cash Flow from Investing Activities
255.00
-88.00
249.00
-141.00
-21.00
-623.00
Cash Flow from Financing Activities
189.00
484.00
17.00
310.00
19.00
634.00
Net Cash Inflow / Outflow
31.00
47.00
-90.00
-75.00
-213.00
427.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Denali Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-512.438
51.533
-563.00
-1094.39%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
0.149
-18.235
18.00
100.82%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-412.6
179.552
-591.00
-329.79%
Cash Flow from Investing Activities
255.281
-129.294
384.00
297.44%
Cash Flow from Financing Activities
189.216
74.006
115.00
155.68%
Net Cash Inflow / Outflow
31.897
123.863
-92.00
-74.25%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
-0.401
0.00
100.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is -18.67% vs 2.88% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
-412.60
-347.69
-18.67%






